Achieved positive adjusted EBITDA for the first time in recent history by growing revenue 8% while slashing operating expenses by 22% in 2025. Performance was bolstered by 16% growth in Q4, driven by strong retina system sales and increased Cyclo G6 probe utilization in the U.S. Strategic shift in glaucoma sales involves using MedScout software to target high-volume MIGS surgeons and mid-range utilization accounts. U.S. Medicare Local Coverage Determinations (LCDs) are actively driving G6 adoption e ...